NACCT 2018

Oct 25, 2018 ‐ Oct 29, 2018


North American Congress of Clinical Toxicology 2018

Enduring CE Materials

Chicago, Illinois, October 25-29, 2018

Requirements for Successful Completion

To claim CE credit for sessions at NACCT 2018 that you did not previously attend, please review the recorded material in its entirety, and then complete the evaluation.

Accreditation and Credit Statements

* Physician:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American Academy of Clinical Toxicology, American Association of Poison Control Centers, American College of Medical Toxicology, Canadian Association of Poison Control Centres, and European Association of Poison Centres and Clinical Toxicologists. The American Academy of Clinical Toxicology is accredited by the ACCME to provide continuing medical education for physicians.

The American Academy of Clinical Toxicology designates this enduring activity for a maximum of 34.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

*Nurses:

Application for Nursing credits has been submitted to the California Board of Nursing.

* Pharmacist:

American Academy of Clinical Toxicology, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Successful completion of this program qualifies for up to 34.5 contact hours. Full attendance per session is required. No partial contact hours will be awarded for partial attendance.

* Certified Health Education Specialists:

The American Academy of Clinical Toxicology is a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. The AAPCC Public Education Track is designated for Certified Health Education Specialists (CHES) to receive up to 13.5 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours available are 12 NCHEC Provider # 101722

The following financial relationships were disclosed; however, no conflict of interest was found and/or was resolved prior to the activity:

Speaker/Planner/Reviewer Financial Relationships

Name (role)

Commercial Interest Name

Type of Relationship

Michael Abesamis/Speaker

Wife on Merck Global Contraception Advisory Board; Site Coordinator-PETAL Network for VIOLET (Vit D Study) Comp; Wife-Medicine 360 Site Investigator IUD Study.

Consultant: Contracted Research; Other

Kavita Babu/Speaker

UpToDate; Medicolegal consulting for CRICO, Traveler's, and Bayer.

Royalty: Consulting

Stephen Borron/Speaker

Safetycall International, PLLC

Ownership Interest

Michele Burns/Speaker

UptoDate Pediatric Toxicology Section Editor

Royalty

Edward Eitzen/Speaker

Consulting for two vaccine companies, PaxVax and Valneva

Consulting

Robert Geller/Speaker

medicolegal chart review

Consulting

Daniel Goldstein/Speaker

Monsanto

Salary and Consulting

Alan Hall/Speaker

Laboratoire Prevor, Valmondois, France

Consulting

Kennon Heard/Speaker/Organizer

McNeil Consumer Heathcare; UpToDate

Contracted Research; Royalty

Kenneth McMartin/Organizer

Mericon Investment Group

Royalty

Robert Middleberg/Speaker

NMS Labs

Salary

Ian Reynolds/Speaker

Teva Pharmaceutical Industries Ltd

Salary; Consulting; Ownership Interest

Darren Robert/Speaker

Novartis; Up-To-Date

Salary (his Partner); royalty

Michael Wolf/Speaker

Med Learning Group, Luto; Amgen, Abbvie, Eli Lilly, Merck

Consulting Fee; Contracted Research

The remaining members of the faculty and planning committee for this conference have indicated that they have no relevant financial relationships to disclose related to the content of the CME activity.

Packages Display Packages

Standard: $125.00
Standard: $125.00

Sessions Included:

ACMT Medical Toxicology: 20th Annual Clinical Pathologic Competition (CPC) (Oct 26, 2018 05:00 PM)

NACCT Keynote Presentation: Organized Crime in Chicago During Prohibition (Oct 27, 2018 08:30 AM)

EAPCCT Scientific Symposium: Toxin Induced Organ Failure (Oct 27, 2018 10:30 AM)

ACMT Practice Symposium: God and Man at the Bar: Addiction, Sobriety and Spirituality (Oct 27, 2018 10:30 AM)

PEC Health Literacy: Best Practices for Effective Educational Messages (Oct 27, 2018 10:30 AM)

AACT Tox History Section: The Past 50 Years (Oct 27, 2018 11:30 AM)

Lightning Oral Abstracts (Oct 27, 2018 11:30 AM)

ABAT Scientific Symposium: From Toxicologist to Entrepreneur: The Basics for Starting a Consulting Business (Oct 27, 2018 11:30 AM)

PEC: Health Information Seeking in the Digital Age: Poison Centers 2008-2017 (Oct 27, 2018 11:30 AM)

Platform Session I - Abstracts #1-8 (Oct 27, 2018 01:30 PM)

AACT Herbal Section Symposium: Herbal Alternatives for Opioid Dependency, Kratom and Ibogaine (Oct 27, 2018 03:45 PM)

AACT Radiation Special Interest Section Symposium: Radiation in Children and Pregnancy - Important Updates for Clinical Toxicologists (Oct 27, 2018 03:45 PM)

PEC AAPCC (American Association of Poison Control Centers) Updates (Oct 27, 2018 03:45 PM)

SPI Roundtable (Oct 27, 2018 03:45 PM)

ACMT Fellows-in-Training Roundtable:The Role of Medico-Legal Consulting in Your Medical Toxicology Career (Oct 27, 2018 04:45 PM)

Updates from the Clinical Toxicology Recommendation Collaborative (Oct 27, 2018 04:45 PM)

AACT Scientific Symposium: Unexplained Somatic Complaints: Differential Diagnosis and Clinical Strategies for Toxicologists (Oct 28, 2018 08:30 AM)

AAPCC SPI Clinical Practice Symposium: Navigating the Gray Areas of Acetaminophen Toxicity (Oct 28, 2018 08:30 AM)

ACMT Scientific Symposium: Hypersensitivity Issues in Occupational Exposures (Oct 28, 2018 10:30 AM)

Lightning Oral Abstracts (Oct 28, 2018 10:30 AM)

AACT Forensics Section Symposium: Witness for the Prosecution: Honing Your Toxicological Expertise as an Expert Witness (Oct 28, 2018 10:30 AM)

PEC: The Data You Don't Know You Need (Including Qualitative Research) (Oct 28, 2018 10:30 AM)

AACT Career Achievement Award: Unsettled Science in Pediatric Environmental Toxicology (Oct 28, 2018 11:30 AM)

AAPCC Veterinary Symposium: What's the Big "D"eal with Cholecalciferol Overdoses? Comparing Human and Animal Overdoses (Oct 28, 2018 11:00 AM)

Platform Session II - Abstracts #9-12 (Oct 28, 2018 01:00 PM)

PEC Substance Misuse & Abuse: Best Practice for Reaching Tweens & Teens (Oct 28, 2018 01:00 PM)

CAPCC Scientific Symposium: Canadian Toxicological Epidemics (Oct 28, 2018 01:00 PM)

SPI Swap and Share (Oct 28, 2018 01:00 PM)

AACT Acute/Intensive Care Symposium: Case Studies (Oct 28, 2018 02:00 PM)

AACT Occupational/Environmental Symposium: Air Quality in Commercial Aircraft Cabins: Investigating the Health Implications of Chemical Contaminants and Ventilation (Oct 28, 2018 02:00 PM)

PEC Opioid Crisis: Misperceptions & Evidenced-Based Solutions (Oct 28, 2018 02:00 PM)

AACT Year in Tox Literature Review 2018: Learn to Read Outside Our Comfort Zone (Oct 28, 2018 03:45 PM)

APAMT Scientific Symposium: Application of Pharmacokinetic Studies (Oct 28, 2018 03:45 PM)

AAPCC SPI Best Practices: Cultivating and Encouraging a Research Environment within the Poison Center (Oct 28, 2018 03:45 PM)

PEC Partnerships with First Responders (Partnerships, Training & Outreach Opportunities) (Oct 28, 2018 03:45 PM)

AAPCC Scientific Symposium: “30 Years of Biodefense and Emerging Infectious Diseases” (Oct 29, 2018 08:30 AM)

Society of Toxicology: Mitochondrial Neurotherapeutics: Past, Present and Future (Oct 29, 2018 08:30 AM)

PEC: E-Cigarettes & Vaping: A Public Health Challenge (Oct 29, 2018 08:30 AM)

AACT Debate: THC - Friend or Foe (Oct 29, 2018 10:30 AM)

Lightning Orals Abstracts (Oct 29, 2018 10:30 AM)

PEC HRSA (Health Resources and Services Administration) Updates (Oct 29, 2018 10:30 AM)

AACT Tox History Section: Chicago Tox History (Oct 29, 2018 11:00 AM)

Platform Session III - Abstracts #13-16 (Oct 29, 2018 12:30 PM)

AACT Pediatric Special Interest Section/ACMT Pediatric Section: Child Maltreatment & Toxicology (Oct 29, 2018 12:30 PM)

PEC: Marijuana: Public Health, Health Policy and Law (Oct 29, 2018 12:30 PM)

ACMT Visiting Professor's Lecture: Pursuing a Research Career as a Medical Toxicology Fellow: The Good, The Bad and The Ugly (Oct 29, 2018 01:30 PM)

Response to Synthetic Cannabinoids and LAARs in Illinois (Oct 29, 2018 01:30 PM)

AACT Sports Section: 50 Years of Performance Enhancing Drugs (Oct 29, 2018 02:45 PM)

PEC Online Tools for Health Information (Helpline Chat & Text Tools, Online Training and Education for Both the General Public & Healthcare Professionals) (Oct 29, 2018 02:45 PM)

AACT Fellows-in-Training Oral Platform Session (Oct 29, 2018 02:45 PM)

Toxicological Jeoparady for SPIs (Oct 29, 2018 02:45 PM)

PEC Swap and Share (Oct 28, 2018 08:30 AM)

Standard: $249.00

Sessions

ACMT Pre-Symposium: Performance and Enhancing Agents 360 (Part 1)

Oct 25, 2018 8:00am ‐ Oct 25, 2018 11:45am

Identification: THUR800

Credits: None available.

Christopher Hoyte, MD
Athletic Performance Enhancing Drugs: In Society

Learning Objectives: 

  1. Identify common athletic performance enhancing drugs used by all people in society.
  2. Discuss the toxicity of these agents.

Daniel Sessions, MD
Analytical Testing for PEDs in the Military

Learning Objectives:

    1. Describe how performance enhancing drug testing in military personnel is executed and reported.
    2. Contrast the Role of a Medical Review Officer (MRO) in the military to an occupational MRO.


    Daniel Sessions, MD
    Management of Positive Tests for Performance Enhancing Drugs: The Process for US Military Personnel

    Learning Objectives:

      1. Discuss Medical Review Officer's role in handling of positive PED test results in US military personnel.
      2. Describe administrative action necessary after a positive PED test result in US military personnel.

      Timothy Liam Epstein, Esq.
      **History of Legal Challenges of Test Results**

      Learning Objectives:

        1. Understand the historical perspective from counsel on the legality/constitutionality of drug testing
        2. Discuss the perspective of counsel defending the rights of a high performer who tests positive.

        Brian Bardsley, EMT-P
        **Athlete Perspective on Performance and Enhancing Agents**

        Learning Objectives:

          1. Explain the perspective of law enforcement and other professionals on performance standards.
          2. Discuss issues with both performance achievement and long term maintenance for individual professionals.


          **Presentation will not be audio recorded**

          Speaker(s):
          Standard: $15.00

          ACMT Pre-Symposium: Performance and Enhancing Agents 360 (Part 2)

          Oct 25, 2018 12:45pm ‐ Oct 25, 2018 4:00pm

          Identification: THUR1245

          Credits: None available.

          Jolie Holschen, MD

          **Providing Care for High Performance & Elite Athletes:  the Sports Medicine Physician’s Perspective on Performance Enhancing Drugs**

          Learning Objectives:

          1. Discuss the role of the physician in educating athletes about the use of banned or harmful over-the-counter substances or prescription medications.
          2. Review the drug testing rules and regulations affecting the treatment of illness/injury in athletes, including threshold use, in and out-of-competition, & TUEs


          Colonel Melissa (Missy) Givens
          Building an Action Hero: Performance Enhancing Supplement Use in U.S. Service Members

          Learning Objectives:

          1. Describe patterns of performance enhancing supplement use in U.S. Service members.
          2. Understand nuances of performance enhancement in U.S service members compared to athletes as it pertains to supplement use.


          Jolie Holschen, MD

          **Equine Drug Testing of Non-Racing Sport Horses; Regulating the Silent Partner

          Learning Objectives:

          1. Examine the role of performance enhancing drugs, diet, exercise, and nutritional supplements on sudden death in athletes through several case studies.
          2. Implement preventative education programs to athletes and coaches and provide physician oversight of exercise regimens


          Stephen Schumacher, DVM
          Equine Drug Testing of Non-Racing Sport Horses; Regulating the Silent Partner

          Learning Objectives:

          1. Identify and understand the challenges in regulating the use of medications in sport horses as compared to human athletes.
          2. Additionally, there are differences in regulating race horses as compared to sport horses.

          George Chiampas, DO
          Behind the Logistics of Drug Testing, Sport Perspective of the Medical Director of Large Scale Events and Teams

          Learning Objectives:

          1. Have a better understanding of the processes and procedures of drug and doping testing in elite Athletes.
          2. Build greater awareness on steps taken to educate athletes on performance enhancing drugs, avoidance and management.

                                             
          Michael Marlin, MD
          Risk and Reward: The Influence of Performance Enhancing Drugs on Amateurs and the General Population
                       

          Learning Objectives:

          1. Become familiar with current abuse trends of specific PEDs in the general population, including emerging drugs of abuse.
          2. Understand the unique risks and adverse effects of PED use in the general population compared to elite athletes and high performers.

          **Presentation will not be audio recorded**

          Speaker(s):
          Standard: $15.00

          AACT Pre-Symposium: 50 Years of Drug Abuse (Part 1)

          Oct 26, 2018 8:00am ‐ Oct 26, 2018 11:45am

          Identification: FRI800

          Credits: None available.

          Kavita Babu, MD
          The LSDetails

          Learning Objectives:

          1. Describe the pharmacology of LSD.
          2. Describe the history of LSD use.


          Kent Olson, MD
          Older sedative-hypnotics

          Learning Objectives:

          1. Describe the pharmacology and toxicology of older sedatives such as barbiturates, glutethimide, ethchlorvynol, and others.
          2. Describe how the pharmacodynamic effects of barbiturates differ from those of benzodiazepines.


          Jeff Lapoint, DO
          Cannabinoids

          Learning Objectives:

          1. Understand the how history and social circumstance affected cannabinoid research, use, and legislation. 
          2. Understand how initial regulatory and legislative actions influenced current trends in cannabinoid use and abuse.


          Robert S. Hoffman, MD

          **Cocaine Then and Now**

          Learning Objectives:

          1. Compare and contrast the physiologic effects of cocaine with those of thyrotoxicosis and pheochromcytoma.
          2. Describe the theoretical reasons why beta blockade would be unwise in acute cocaine toxicity.

          Trevonne Thompson, MD
          Adulterants

          Learning Objectives:

          1. Describe the historical role adulterants have played in illicit drug use.
          2. Describe the pathophysiology of select adulterants.


          Sean Bryant, MD
          Phencyclidine - Shadows, Serenity, & Seraphim

          Learning Objectives:

          1. Appreciate the history of phencyclidine use and abuse.
          2. Understand phencyclidine's various pharmacologic actions and clinical manifestations.


          Amy Zosel, MD
          Inhalant Abuse

          Learning Objectives:

          1. Describe different methods of inhalant abuse.
          2. Differentiate acute and chronic inhalant toxicity.
          3. Understand unique toxicities associated with specific inhalants.

          **Presentation will not be audio recorded**

              Speaker(s):
              Standard: $15.00

              AACT Pre-Symposium: 50 Years of Drug Abuse (Part 2)

              Oct 26, 2018 12:45pm ‐ Oct 26, 2018 4:30pm

              Identification: FRI1245

              Credits: None available.

              Frank LoVecchio, DO, MPH
              History of Methamphetamine

              Learning Objectives:

              1. Discuss the History of Methamphetamine.
              2. Discuss signs and symptoms of Methamphetamine toxicity.


              David Wood, MD
              The Cathinones


              Learning Objectives:

              1. Understand the history of the cathinone group of novel psychoactive substances.
              2. Describe the acute toxicity related to the recreational use of cathinones.

              Janetta Iwanicki, MD
              Synthetic Cannabinoids

              Learning Objectives:

              1. Identify common presenting symptoms in patients with synthetic cannabinoid toxicity.
              2. Identify common treatments for symptomatic patients with synthetic cannbinoid toxicity.


              Daniel E. Rusyniak, MD
              MDMA, Molly, NBOme

              Learning Objectives:

              1. Discuss the mechanism of MDMA-mediated hyperthermia.
              2. Discuss the environmental contributors to MDMA-mediated toxicity.


              Elizabeth Moore, DO
              Novel Psychoactive Drugs

              Learning Objectives:

              1. Identify clinical toxicity associated with novel psychoactive drugs of abuse.
              2. Review the history and development of novel psychoactive drugs.


              William Eggleston, PharmD 
              Natural Products of Abuse   
               

              Learning Objective:

              1. Discuss the history and legal status of ayahuasca, ibogaine, and kratom in the United States and Canada. 

              Cori Rizman
              ** The Evolution of Drug Trafficking in the United States**

              Learning Objectives:

              1. Understand how drug trends have changed over time and the ways in which they are infiltrated into the supply chain (both legitmiate and rogue).

              Jeanmarie Perrone, MD
              Opioids

              Learning Objectives:

              1. Provide an overview and historical perspective of the opioid crisis on a national level.
              2. Describe the rationale for judicious opioid use.

              ** Presentation will not be audio recorded**

              Speaker(s):
              Standard: $15.00

              ACMT Medical Toxicology: 20th Annual Clinical Pathologic Competition (CPC)

              Oct 26, 2018 5:00pm ‐ Oct 26, 2018 7:00pm

              Identification: FRI500

              Credits: None available.

              Evan Bradley, MD, PhD
              20th Annual Clinical Pathologic Competition (CPC)

              Learning Objectives:

              1. Generate a good differential diagnosis of anion gap metabolic acidosis.
              2. Understand the patholophysiology of SGLT1i induced ketoacidosis.

              Caitlin Bonney, MD
              20th Annual Clinical Pathologic Competition (CPC)

              Learning Objective:

              1. Describe the management of several unique poisonings.

              Eric McGillis, MD
              20th Annual Clinical Pathologic Competition (CPC)

              Learning Objective:

              1. Identify potential pitfalls in the diagnostic approach to poisoned patients.

              Speaker(s):
              Standard: $15.00

              PEC Health Literacy: Best Practices for Effective Educational Messages

              Oct 27, 2018 10:30am ‐ Oct 27, 2018 11:30am

              Identification: SAT1030C

              Credits: None available.

              Michael S. Wolf, PhD
              PEC Health Literacy: Best Practices for Effective Educational Messages

              Learning Objectives:

              1. Identify 3 health system targets for health literacy interventions and how each impact patient engagement and outcomes.
              2. Provide 2 examples of how clinical workflows can be modified to accommodate better patient-provider communication.

              Speaker(s):
              Standard: $15.00

              EAPCCT Scientific Symposium: Toxin Induced Organ Failure

              Oct 27, 2018 10:30am ‐ Oct 27, 2018 11:30am

              Identification: SAT1030A

              Credits: None available.

              Raido Paasma, MD, PhD
              Is there a place for non-invasive mechanical ventilation and high-flow nasal cannulae to treat drug-induced respiratory failure?

              Learning Objectives:

              1. Discuss about use of non-invasive ventilation in case of acute poisoning.
              2. Compare CPAP ventilation and high-flow nasal oxygen therapy.


              Florian Eyer, MD
              Are new vasopressors and inotropic drugs useful to treat drug-related cardiovascular failure?

              Learning Objectives:

              1. Acknowledge benefits and risks of classic vasopressors and more recent inotropes in the management of toxin-induced cardiovascular failure.
              2. Describe the role of levosimendan in the treatment of cardiovascular failure induced by toxins.


              Bruno Mégarbane, MD, PhD
              ECMO to treat acute poisonings: indications and results 

              Learning Objectives:

              1. To identify the best indications for veno-arterial ECMO in acute poisonings.
              2. To know how to monitor the poisoned patient treated with veno-arterial ECMO.



              Speaker(s):
              Standard: $15.00

              ACMT Practice Symposium: God and Man at the Bar: Addiction, Sobriety and Spirituality

              Oct 27, 2018 10:30am ‐ Oct 27, 2018 11:30am

              Identification: SAT1030B

              Credits: None available.

              Gerald O'Malley, DO
              God and Man at the Bar: Addiction, Sobriety and Spirituality

              Learning Objectives:

              1. Describe the methods by which addicts from different religious and cultural backgrounds access spirituality to achieve and maintain sobriety.
              2. Describe the relative importance and influence of spirituality in the approach to drug and alcohol addiction and rehabilitation.

              Rachel Haroz, MD
              God and Man at the Bar: Addiction, Sobriety and Spirituality

              Learning Objectives:

              1. Describe the methods by which addicts from different religious and cultural backgrounds access spirituality to achieve and maintain sobriety.
              2. Describe the relative importance and influence of spirituality in the approach to drug and alcohol addiction and rehabilitation.

              Speaker(s):
              Standard: $15.00

              AACT Tox History Section: The Past 50 Years

              Oct 27, 2018 11:30am ‐ Oct 27, 2018 12:30pm

              Identification: SAT1130A

              Credits: None available.

              Howard McKinney, PharmD
              AACT Tox History Section: The Past 50 Years

              Learning Objectives:

              1. Review the history of AACT.
              2. Review a selection of the people in and accomplishments of AACT.

              Mark Winter, PhD
              AACT Tox History Section: The Past 50 Years

              Learning Objectives:

              1. Review the history of AACT.
              2. Review a selection of the people in and accomplishments of AACT.




              Speaker(s):
              Standard: $15.00

              Lightning Oral AbstractsLightning Oral Abstracts

              Preview Available

              Lightning Oral Abstracts

              Oct 27, 2018 11:30am ‐ Oct 27, 2018 12:15pm

              Identification: SAT1130B

              Credits: None available.

              Gillian Beauchamp, MD
              # 28 Impact of Legislation Legalizing Recreational Marijuana Sales on Cannabis Exposure Calls to Poison Centers 2008-2017

              Learning Objectives:

              1. State the age range and sex of cases most commonly reported to poison centers for cannabis exposure between 2008-2017.
              2. State whether states with legalized recreational cannabis had an increase or decrease in cannabis-related calls to poison centers.


              Rittirak Othong, MD
              # 29 Clinical Prediction Rule for Torsade de Pointes in Patients with Drug-Induced QT Prolongation

              Learning Objective:

              1. Identify risk factors and patients at risk for drug induced torsade de pointes.


              Sean Boley, MD
              # 30 A Comparison of Resource Utilization and Adverse Events Related to the Management of Anticholinergic Delirium between Physostigmine and Non-Antidote Therapy

              Learning Objective:

              1. Better understand the effectiveness of physostigmine as well as it's effect on resource utilization and development of adverse events.


              Rachel Gorodetsky, PharmD
              # 119 Five years of Physo: a Retrospective Review of the Safety and Efficacy of Physostigmine Use atan Academic Tertiary Care Hospital

              Learning Objectives:

              1. Describe the most common exposures for which physostigmine was used in this case series.
              2. Discuss the incidence of adverse effects to physostigmine in this case series.


              David Perez Lauterbach, MD
              # 191 Dose-Dependent Pulmonary Injury Following Kinepak Exposure,

              Learning Objective:

              1. Recognize nitrogen dioxide related lung injury in uncommon presentations.


              Speaker(s):
              Standard: $15.00
              Print Certificate
              Review Answers
              Print Transcript
              Completed on: token-completed_on
              Review Answers
              Please select the appropriate credit type:
              /
              test_id: 
              credits: 
              completed on: 
              rendered in: 
              * - Indicates answer is required.
              token-content

              token-speaker-name
              token-index
              token-content
              token-index
              token-content
              token-index
              token-content
              token-index
              token-content
              token-index
              token-content
              token-index
              token-content
              /
              /
              token-index
              token-content
              token-index
              token-content